A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) — TALLY

Cognitive Impairment Associated With Schizophrenia Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Status Completed

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cognitive Dysfunction
Cognitive Impairment Associated With Schizophrenia
Schizophrenia

Clinical Trial Details

NCT number	NCT03745820
Study type	Interventional
Source	Biogen
Contact
Status	Completed
Phase	Phase 2
Start date	November 15, 2018
Completion date	April 7, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT00604760` - Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia	Phase 2
	Completed	`NCT05136690` - Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)	Phase 1